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Abstract
Background: The annual relapse rate has been commonly used as a primary efficacy endpoint in
phase III multiple sclerosis (MS) clinical trials. The aim of this study was to determine the
relative contribution of different possible prognostic factors available at baseline to the on-study
relapse rate in MS. Methods: A total of 821 patients from the placebo arms of the Sylvia Lawry
Centre for Multiple Sclerosis Research (SLCMSR) database were available for this analysis. The
univariate relationships between on-study relapse rate and the baseline demographic, clinical, and
MRI-based predictors were assessed. The multiple relationships were then examined using a
Poisson regression model. Two predictor subsets were selected. Subset 1 included age at disease
onset, disease duration, gender, Expanded Disability Status Scale (EDSS) at baseline, number of
relapses in the last 24 months prior to baseline, and the disease course (RR and SP). Subset 2
consisted of Subset 1 plus gadolinium enhancement status in MRI. The number of patients for
developing the models with no missing values was 727 for Subset 1 and 306 for Subset 2.
Results: The univariate relationships show that the on-study relapse rate was higher for younger
and for female patients, for RR patients than for SP patients, and for patients with positive
enhancement status at entry (Wilcoxon test, p<0.05). A higher on-study relapse rate was
associated with a shorter disease duration, lower entry EDSS, more pre-study relapses and more
enhancing lesions in T1 at entry. The fitted Poisson model shows that disease duration
(estimate=-0.02) and previous relapse number (estimate=0.59 for 1, 0.91 for 2 and 1.45 for 3 or
more relapses vs 0 relapse) remain. We were able to confirm these findings in a second,
independent dataset.  Conclusions: The relapse number prior to entry into clinical trials together
with disease duration are the best predictors for the on-study relapse rate. Disease course and
gadolinium enhancement status, given the other covariates, have no significant influence on the
on-study relapse rate. 
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Introduction
Since the results of the pivotal trial of interferon -1b were reported in 1993,1 the annual relapse
rate has been commonly used as a primary efficacy endpoint in phase III clinical trials for
relapsing-remitting (RR) and as secondary outcome for studies with secondary progressive (SP)
multiple sclerosis (MS) patients.2-10 These trials demonstrated a reduction of the annual relapse
rate.1-10 Most of the trials enrolled patients with a history of at least two relapses in the two years
prior to entry,1,3,4,6,7,9 being 15 – 64 years old,1,2,4-10 having more than one year of disease
duration,1,2,7,10and with Expanded Disability Status Scale (EDSS) scores within a range below 6.0
for RR patients1-3,6,7,9,10 and 3.0 – 6.5 for SP patients.4,5,8 
Several studies addressed the relationship between relapse rate and demographic and clinical
factors. For subjects in natural history cohorts, Weinshenker11 and Ebers12 summarized the results
from several studies which showed that the relapse rate was higher in younger patients, also
higher for patients with a shorter disease duration, and was not correlated with the clinical
course.13 In a 9-month, placebo-controlled study14 it was also found that the on-study relapse rate
was correlated with the number of relapses during the two years before entry into study.
However, the magnitude of the effects of these baseline demographic and clinical variables on
the annual on-study relapse rate was only examined univariately.
It was assumed that it is the inflammatory aspect of the lesions as seen in magnetic resonance
imaging (MRI) that is in closest relation to relapses.15 In consequence the lesion numbers on MRI
have been proposed as predictors for the occurrence of subsequent relapses.16 However, studies
showed that there was only a weak univariate correlation of MRI-based measures, especially
gadolinium enhancing lesions at baseline and on-study relapse rate, visible in MS patients.14,17 
Held, U et al. 5
The aim of this study was to determine the relative contribution of a large set of different
possible prognostic factors for the on-study relapse rate in MS in a multiple regression model.
This would help to select patients more efficiently for clinical trials that use relapse rate as a
primary endpoint.
Methods
Patients and variables
A total of 821 RR and SP patients from the placebo arms of RCTs in the “open” part of the
SLCMSR database were available for the analysis. Each release of the SLCMSR database is
divided into an “open” and a “closed” : a working sample and a validation sample. The main
hypotheses generated from an analysis of the “open” portion are then retested in a second,
confirmatory validation step using the “closed” part of the database prior to submitting the results
for publication. 
The on-study relapse rate as response variable was referred to as the number of relapses during
the first year of the study. The lower boundary for the first year was fixed at 330 days, which
means that patients observed shorter than 330 days were excluded from the analysis. For some
patients we have information only about the number of relapses in a certain time interval which
does  not  necessarily  coincide  with  the  one  year  observation  period  we  are  interested  in.
Therefore, these relapses were counted proportionally and as a consequence some of the relapse
rates are non-integers. 
If the follow-up period is extended from one to two years (lower boundary 690 days), the number
of patients drops to 620 (256 RR and 364 SP). However, as the 2-year follow-up on relapse rate
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is relevant for phase III trials, we will report on the corresponding results along the lines of the
one year analyses.
Variables selected as possible predictors at baseline for the on-study relapse rate include
continuous variables (age at disease onset, disease duration (time since first symptom), T2 lesion
volume), ordinal variables (EDSS, number of relapses in the 12 and 24 months prior to entry into
the study, number of enhancing lesions in T1), and binary variables (gender, disease course (RR
vs SP) and gadolinium enhancement status in T1). All patients had to be free of relapses at entry
into the study.  
Statistical methods
The univariate relationships between the on-study relapse rate and baseline explanatory variables
were assessed by the Wilcoxon rank sum statistic for binary predictors and Spearman’s rank
correlation coefficient for continuous and ordinal predictors. 
Next, the multiple relationships were examined using a Poisson regression model. The non-
integer on-study relapse numbers were rounded. To check if overdispersion was present, a quasi-
likelihood model was fitted with all covariates. The estimated overdispersion parameter was
close to 1, hence it seemed appropriate to use regular Poisson regression and Akaike’s
information criterion (AIC) to develop the model,18,19 and then obtain the final estimates by a
quasi-Poisson model.18 Initial models with all covariates were developed with a stepwise model
selection procedure based on minimizing the AIC. To limit the tendency of this automatic
procedure to favour a complex model, the stepwise procedure was terminated if selected
predictors failed to achieve significance at a 5% level. Predictor subsets were selected based on
statistical, clinical, and data availability considerations. Subset 1 initially included age at disease
onset, disease duration, gender, EDSS at baseline, number of pre-study relapses in the last 24
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months, and the disease course (RR or SP). Data on gadolinium enhancement status was not
included in this subset for maintaining the sample size, but the potential importance of this
predictor was considered in Subset 2, consisting of all predictors in Subset 1 plus gadolinium
enhancement status. Considering the high variability between individual raters and image
analysis centres20 (personal communication with Prof. Schach about heterogeneity in pooled MS
trials which cannot be explained by clinical and demographic differences alone) for determining
the number of enhancing lesions we have condensed this information to enhancement status.
Both EDSS scores and the number of relapses in the last 24 months prior to entry into the trials
were treated as categorical variables (three categories with similar number of patients for EDSS:
0-3.0, 3.5-5.0, and 5.5 or above; four categories for prior relapse number: 0, 1, 2, and 3 or more).
The number of patients with complete observations for all of these variables was 727 (332 RR
and 395 SP patients) for Subset 1 and 306 (174 RR and 132 SP patients) for Subset 2. The 2-year
analysis included 585 patients in Subset 1, and 183 patients in Subset 2.
Expansions of these initial models were considered allowing interactions between included
predictors. Following the final fitted models, the confidence intervals for the predicted mean on-
study relapse rate were computed. 
The original set of 821 patients decreased quite considerably when fitting the predictors in the
multiple models, especially for Subset 2. In order to address the question of selection bias, we
performed a homogeneity analysis and compared the patients of Subset 1 and Subset 2 with their
missing counterparts from the total of 821 patients (94 for Subset 1 and 515 for Subset 2,
respectively). We compared the patient groups with respect to the distribution of the variables
age at onset, disease duration, gender, EDSS, pre-study relapses, enhancement status, disease
course and the on-study relapse rate, and found no major differences. The only discrepancies we
found were in the 94 patients corresponding to Subset 1. They seemed to have somewhat shorter
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disease duration (8.16 years versus 10.77 years), a slightly higher previous relapse rate (2.67
versus 1.94), and a larger percentage of RR patients (70.21% versus 45.67%). 
Following completion of the analyses in the “open” part of the database, a summary of the major
findings was prepared. A detailed proposal for specific analyses required to confirm these
findings was approved by the SLCMSR Publication Committee. The SLCMSR data trustees then
executed these analyses in the “closed” part of the database.
Results
Descriptive statistics
The “open” part of the dataset available for the analysis was derived from nine different image
analysis centres. The inclusion criteria were not identical among the clinical trials, however, we
expect the potential heterogeneity in mean age, duration of the disease, EDSS scores, and relapse
rate prior to entry to study to be captured by the multiple regression models. The on-study relapse
rate was available for a total of 821 placebo patients, where 398 patients were diagnosed with
RRMS and 423 patients with SPMS. As the individual trials differed in entry criteria and
variables collected, the number of patients with data available differed depending on the
particular explanatory variables being studied. The descriptive statistics are shown in Table 1.
Table 1 about here.
The demographic and clinical data of patients in the two subsets are shown in Table 2.
Table 2 about here.
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Univariate analysis
The Spearman rank correlation coefficient (r) for the continuous variables and the Wilcoxon rank
sum statistic for the binary predictors were used to assess the relationship with on-study relapse
rate, which is shown in Table 3.
Table 3 about here.
The results show that the on-study relapse rate was larger for RR patients than for SP patients,
also for younger and for female patients, and for patients with positive enhancement status at
entry. A higher on-study relapse rate was associated with a shorter disease duration, and lower
entry EDSS. Patients who had more previous relapses or more enhancing lesions in T1 tended to
have a higher on-study relapse rate. There was no significant relationship between on-study
relapse rate and T2 lesion volume at entry. Thus, this predictor was not considered any further in
the multiple regression models.
In Table 4, the on-study relapse rate was then compared between RR and SP patients stratified by
the previous relapses (0, 1, 2, and 3 or more relapses). 
Table 4 about here.
None of the between-group comparisons was significant at a 5% level, i.e. given the number of
relapses in the last 24 months, the on-study relapse rate did not significantly differ for RR and SP
patients.
We also compared the on-study relapse rate between patients with no or at least one enhancing
lesion for 0, 1, 2, 3 or more previous relapses. The results are described in Table 5, and again we
found no significant difference between gadolinium status groups.
Table 5 about here.
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Poisson regression analysis
The initial fit of the model for Subset 1 with all the covariates returned an overdispersion
parameter of 1.10. This shows that the estimated standard errors for the effects are slightly too
small. Then the stepwise model selection procedure based on the AIC criterion included disease
duration, relapse number in the last 24 months, and age at onset into the model, in which disease
duration and relapse number in the last 24 months were significant at a 5% level. The model with
the three predictors was not significantly better than the model with the two significant predictors
as described above (the likelihood ratio test statistic was 2.99 with 1 degree of freedom, p=0.08).
Adding an interaction between disease duration and previous relapse number into the model did
not improve the model fit significantly (p=0.65). And there was no enlargement in sample size
when refitting the model only with these two predictors. 
For Subset 2, which includes gadolinium enhancement status, the overdispersion parameter in
the initial model with all the covariates was 1.13, then the stepwise selection procedure based on
the AIC criterion was used for model development. Only relapse number in the last 24 months
was significant at a 5% level. Thus given the pre-study relapse number, no significant effect of
Gadolinium enhancement status could be shown in this smaller subset. On the other hand, if
gadolinium enhancement was the only predictor for modeling on-study relapse rate, then the p-
value was found to be 0.030. However, when using the predictors identified in Subset 1 (relapse
number in last 24 months and disease duration) the additional inclusion of the variable
gadolinium enhancement led to a p-value of 0.152, thus no longer significant. Therefore, the final
model could only be based on Subset 1. The fitted model is described in Table 6, where the
standard errors were adjusted for the estimated overdispersion.
Table 6 about here.
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The results show that a longer disease duration is associated with a lower on-study relapse rate;
the more relapses were observed prior to entry to the study, the higher is the on-study relapse
rate. 
The model selection on Subset 1 for the 2-year follow-up arrived at the same final model: the
relapse number in prior 24 months and disease duration are the best clinical predictors, and both
are significant at a 5% level. The effect sizes and p-values of the predictors are nearly identical to
the ones obtained for the 1-year analysis. The estimate of the intercept changed from -0.93 in the
1-year follow up to -0.22 for the 2-year results to explain the higher relapse rate level when
considering the extended observation period.
 In Subset 2, the univariate influence of enhancement status on the 2-year on-study relapse rate
yields a p-value of 0.07, and thus the final model can be based on Subset 1.
Predicted on-study relapse rate
The predicted on-study relapse rate and corresponding 95% confidence intervals for the mean
were calculated based on the fitted Poisson regression model with overdispersion. These are
shown in Table 7. 
Table 7 about here.
Validation results
The “closed” part of the SLCMSR database release that was held back for confirmation of
hypotheses contained 1047 RR and SP patients with information on the relapse rate for the first
year on trial. Distribution with respect to disease course, on-study relapse rate, attack number in
Held, U et al. 12
24 months prior to study entry, baseline EDSS and enhancement status were very similar in the
“open” and “closed” parts, indicating they were comparable and suitable for the purpose of
validation. 
Significant univariate relationships were confirmed for the important predictors selected in the
multiple regression analyses for Subset 1. These included the correlation of disease duration, and
attack number last 24 months with the on-study relapse rate, and the comparison of the relapse
rate of patients with and without positive enhancement status.
Validation of the multiple Poisson regression model for Subset 1 revealed a significant effect of
disease duration, and attack number in the last 24 months. On Subset 2, we first fitted a Poisson
model with the predictor enhancement status alone, which gave p=0.005. Along the lines of the
analyses in the “open” part, we assessed the importance of enhancement status if it enters as an
additional predictor given disease duration and prior attack number. The resulting p-value for
enhancement status in the multiple Poisson model was then 0.09, which corresponds exactly to
the results obtained in the “open” part.
In summary, we were able to validate all findings in the “closed” portion of the data release,
including the result that gadolinium enhancement status alone is a significant predictor for the
on-study relapse rate in the first year. However, when it enters in the multiple model, its
significance diminishes compared to the clinical predictors disease duration and attacks prior 24
months.
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Discussion
Although only a part of the entire database could be used for this study, the number of 821
placebo patients studied was still a magnitude larger than that seen in a typical phase III clinical
trial (commonly 100-500 patients per arm). Additionally, in using data from several trials, the
possibility of selection bias is reduced. 
The results revealed modest but nevertheless significant relationships between on-study relapse
rate and various clinical and MRI-based determinants including disease course, disease duration,
gender, age at disease onset, EDSS at baseline, relapse rate prior to entry into the study, and
enhancing lesion numbers in T1. 
Some variables retained considerable prognostic value even in a multiple regression approach
including number of relapses in the last 24 months and disease duration, and these findings were
unequivocally confirmed in the “closed” part of the SLCMSR database. As such, the utility of the
Poisson regression model would be primarily in defining the expected on-study relapse rate in
groups of patients considered for clinical trials. The mean on-study relapse rate could therefore
be predicted by pre-study relapse number and disease duration. This is illustrated in Table 6: if
we take a patient with 10 years of MS, the predicted on-study relapse rate for the patients with 0,
1, 2 and 3 or more relapses in the previous two years would be 0.33, 0.60, 0.83, and 1.43,
respectively. 
The results for a 2-year follow-up are very similar to the ones obtained in the first year – even
though they are based on 25% less patients: model selection on Subset 1 arrived at the same
model for the 2-year rates including disease duration, and number of relapses in last 24 months
as best clinical predictors. The effect sizes and p-values corresponded well to the results for the
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first year. However, for Subset 2, even the univariate contribution of enhancement status is not
significant.
Another implication of these findings includes the role of relapse number prior to study entry and
disease duration as stratification criteria for the randomization of the patients in placebo and
treatment arms of a clinical trial. If not used as such, they should alternatively be adjusted for as
covariates in the statistical analysis when demonstrating the treatment effect.
Furthermore, we found that the disease course does not have a significant contribution to the
multiple model although its contribution appears as significant in the univariate analysis. This is
due to the association of disease course and previous relapse number (the correlation coefficient
between these two variables is 0.59). The effect of the disease course is captured by the pre-study
relapse number, which can be seen in Table 4. This implies for future trials, that the enrolment
should rather be based on the relapse number in the last 24 months than on the disease course. 
The value of enhanced MRI for predicting clinical outcomes has not been well established. A
longitudinal study found a correlation between enhanced MRI lesions at entry and the relapse
rate in the next year.21 However, another meta-analysis from five natural course studies and four
placebo groups of clinical trials showed that the relationship between gadolinium enhancement
status at baseline and relapse rate was only marginal.17 In the current study, in the univariate
comparison gadolinium enhancement was significantly correlated with on-study relapse rate. The
trend towards an increase of the on-study relapse rate in patients with enhanced lesions is
depicted in Table 5. However, in the multiple model the predictive value decreased when the
other clinical covariates entered. Several reasons for this finding are possible. Enhanced MRI is
able to detect the inflammatory activity of the disease with high sensitivity. But, some lesions
might be clinically silent, i.e., damage to the central nervous system pathways is not reflected in
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the clinical symptoms or signs. About 50 percent of the patients will have at least one
gadolinium-enhancing lesion at any given time. However, different patients contribute at
different time points and a large proportion of these lesions are not associated with clinical
manifestations. Gadolinium-enhancing lesions occur up to ten times more often than clinical
relapses.22 Another reason for this lack of relationship may be related to the pathology of MS
lesions. Gadolinium enhancement depicts local breakdown of the blood-brain barrier and to some
extent inflammatory infiltration. When taking recent evidence about a more complex role of the
immune system in the pathogenesis of MS into account23, this may or may not be followed by
demyelination and axonal injury and clinically detectable deficits.
This study provides information about the predictive role of demographic, clinical, and MRI-
based parameters on the on-study relapse rate. The benefit of the model fitted in this study is that
inclusion or exclusion of a patient into a clinical trial could be based on a predicted relapse rate
rather than on a single demographic or clinical characteristic. In particular, patients selected for
relapse intervention trials  should usually meet a  relapse rate  criterion which depends on the
number of relapses in the two years pre-trial and disease duration.    
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Table 1. Descriptive statistics of the predictor variables
Variable Statistic Total RRMS SPMS
On-study
relapse rate
N
Mean (SD)
Median
Range
821
0.88 (1.16)
0
0 – 7
                    398
1.12 (1.23)   
1
0 – 7
423
0.65 (1.05)
0
0 – 6
Gender N
Male
Female
821 (100.00%)
292 (35.57%)
529 (64.43%)
398 (100.00%)
115 (28.89%)
283 (71.11%)
423 (100.00%)
177 (41.84 %)
246 (58.16 %)
Age at
onset
(years)
N
Mean (SD)
Median
Range
815
29.37 (7.87)
29
4 – 57
394
28.61 (7.22)
28
10 - 53
421
30.08 (8.38)
29
4 – 57
Disease
duration
(years)
N
Mean (SD)
Median
Range
815
10.49 (7.65)
8.50
0.50 – 40.92
394
7.14 (6.10)
5.42
0.50 - 37.67
421
13.61 (7.65)
12.50
1.33 - 40.92
EDSS N
0.0 – 3.0
3.5 – 5.0
5.5 – 8.0
821
262 (31.91%) 
290 (35.32%)
269 (32.77%)
398
253 (63.57%)
122 (30.65%)
23 (5.78%)
423
9 (2.13%)
168 (39.72%)
246 (58.15%)
Relapses
during last
12 months
N
Mean (SD)
Median
Range
672
0.90 (0.98)
1
0 – 5
302
1.46 (0.98)
1
0 - 5
370
0.44 (0.70)
0
0 - 3
Relapses
during last
24 months
N
Mean (SD)
Median
Range
733
1.95 (1.69)
2
0 – 9
336
2.93 (1.47)
3
0 - 9
397
1.12 (1.40)
1
0 - 8
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T2 lesion
volume
(cm3)
N
Mean (SD)
Median
Range
554
21.24 (19.69)
16.02
0.07 – 135.44
206
17.81 (18.06)
12.68
0.07 – 128.60
348
23.27 (20.35)
18.37
0.20 – 135.44
Number of
enhancing
lesions in
T1
N
Mean (SD)
Median
Range
382
2.45 (4.84)
1
0 – 47
232
2.81 (5.57)
1
0 - 47 
150
1.88 (3.35)
0
0 - 16
Gd. Enh.
lesions
N
At least one/ 
None 
382
210 (54.97%)
172 (45.03%)
232 (100.00%)
133 (57.33%)  
              99 (42.67%)
150 (100.00%)
77 (51.33%)  
              73 (48.67%)
SD=standard deviation, Gd. enh. lesions=Gadolinium enhancing lesions
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Table 2. Demographics of patients in the two subsets
Variable Statistic Subset 1 Subset 2
RRMS
(N=332)
SPMS (N=395) RRMS (N=174) SPMS (N=132)
On-study
relapse rate
Mean (SD)
Median
Range
1.17 (1.23)
1
0 – 6
0.62 (0.98)
0
0 – 6
1.10 (1.22)
1
0 – 5
0.70 (1.15)
0
0 – 6
Age at onset
(years)
Mean (SD)
Median
Range
28.25 (6.92)
28
13 – 48
30.07 (8.38)
29
4 – 57
28.39 (7.28)
28
13 – 48
29.63 (8.33)
29
4 – 48
Disease
duration
(years)
Mean (SD)
Median
Range
7.27 (6.10)
5.50
0.67 – 34.83
13.71 (7.67)
12.67
1.33 – 40.92
7.85 (6.56)
5.92
0.67 – 34.83
13.61 (8.07)
12.21
1.67 – 40.92
EDSS 0.0 – 3.0
3.5 – 5.0
5.5 – 8.0
219 (65.96%)
  96 (28.92%)
  17 (5.12%)
    8 (2.03%)
164 (41.52 %)
223 (56.46%)
112 (64.73%)
  46  (26.44%)
  16 (9.20%)
  2 (1.52%)
49 (37.12%)
81 (61.36%)
Number of
relapses last
24 months
Mean (SD)
Median
Range
2.93 (1.48)
3
0 – 9
1.11 (1.40)
1
0 – 8
2.74 (1.53)
2
0 – 9
0.98 (1.47)
0
0 – 8
Gender Male
Female
  94 (28.3%)
238 (71.7%)
163 (41.3%)
232 (58.7%)
  49 (28.2%)
125 (71.8%)
  61 (46.2%)
  71 (53.8%)
Gd. Enh.
lesions
At least one /
none 
_ _ 111 (63.8%)
  63 (36.2%)
  66 (50.0%)
  66 (50.0%)
SD=standard deviation, Gd. enh. lesions=Gadolinium enhancing lesions
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Table 3. Univariate relationships between the explanatory variables and on-study relapse
rate
Predictor Relationship p-value
Disease course
Gender
Age at onset
Duration of disease
EDSS
Number of relapses in last 12 months
Number of relapses in last 24 months
T2 lesion volume
Number of enhancing lesions in T1
Enhancement status
RR > SP 
Female > Male
r = -0.07
r = -0.23
r = -0.18
r = 0.39
r = 0.42
r = -0.01
r = 0.15
At least 1 lesion > No lesion
<0.001
0.048
0.048
<0.001
<0.001
<0.001
<0.001
0.785
0.003
0.011
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Table 4. On-study relapse rate for RR and SP patients stratified by previous relapses
Relapses in
last 24 months
Disease course
Statistic for on-study relapse rate RR SP
0
1
2
3 or more
N
Mean (SD)
N
Mean (SD)
N
Mean (SD)
N
Mean (SD)
5
0.40 (0.89)
28
0.43 (0.69)
121
0.92 (1.02)
182
1.48 (1.32)
182
0.31 (0.63)
83
0.61 (0.82)
82
0.74 (0.98)
50
1.58 (1.51)
SD=standard deviation
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Table 5. On-study relapse rate for enhancement status stratified by previous relapses
Relapses in
last 24 months
Enhancement status at baseline
Statistic for on-study relapse rate No enhancing lesion At least 1 lesion
0
1
2
3 or more
N
Mean (SD)
N
Mean (SD)
N
Mean (SD)
N
Mean (SD)
39
0.33 (0.62)
25
0.44 (0.77)
31
0.71 (0.83)
38
1.42 (1.29)
34
0.5 (0.86)
26
0.58 (0.86)
53
0.91 (1.10)
66
1.65 (1.53)
SD=standard deviation
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Table 6. Fitted Poisson regression model to predict on-study relapse rate
Predictor Estimate Std. Error P-value
Disease duration (years)
Relapse number last 24 months* 
(1 vs 0 relapse)
(2 vs 0 relapse)
(3 or more vs 0 relapse)
-0.02
  
 0.59
 0.91
 1.45
0.01
0.20
0.17
0.16
0.015
0.003
<0.001
<0.001
* 187 (25.7%) patients had 0 relapse; 111 (15.3%) patients had 1 relapse; 200 (27.5%) patients
had 2 relapses; 229 (31.5%) patients had 3 or more relapses.     
Held, U et al. 27
Table 7. Predicted mean relapse rate for Model 1
Relapses in
prior 24 months
Disease duration
(years)
Predicted
mean
95% Confidence interval
0 0 0.40           [ 0.28 ; 0.56 ]
5 0.36           [ 0.27 ; 0.49 ]
10 0.33           [ 0.25 ; 0.45 ]
15 0.31           [ 0.23 ; 0.41 ]
20 0.28           [ 0.21 ; 0.38 ]
1 0 0.71           [ 0.51 ; 0.98 ]
5 0.65     [ 0.49 ; 0.88 ]
10 0.60     [ 0.46 ; 0.79 ]
15 0.55     [ 0.42 ; 0.72 ]
20 0.51     [ 0.38 ; 0.68 ]
2 0 0.99     [ 0.80 ; 1.21 ]
5 0.91     [ 0.76 ; 1.08 ]
10 0.83     [ 0.70 ; 0.98 ]
15 0.76     [ 0.63 ; 0.92 ]
20 0.70     [ 0.56 ; 0.88 ]
3 or more 0 1.69     [ 1.46 ; 1.96 ]
5 1.55     [ 1.38 ; 1.75 ]
10 1.43     [ 1.26 ; 1.62 ]
15 1.31     [ 1.11 ; 1.54 ]
20 1.20     [ 0.97 ; 1.50 ]
